- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01605864
Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia (CAP)
Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital
Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP. Usually, hospitalized persons with CAP are given two antibiotics together. These antibiotics usually include a cephalosporin and a macrolide. The most commonly used cephalosporin at Albany Medical Center Hospital is ceftriaxone. The most commonly used macrolides at Albany Medical Center Hospital are azithromycin and doxycycline.
This research is being done to find out how well a new cephalosporin antibiotic, called ceftaroline, works in combination with a macrolide for the treatment of CAP. Ceftaroline is similar to ceftriaxone. Ceftaroline was recently approved by the FDA to treat pneumonia in hospitalized patients based on two research studies. In one study, ceftaroline was better than ceftriaxone. In the second study, ceftaroline was just as good as ceftriaxone. Ceftaroline was very well tolerated in both clinical studies and it was found to be as safe as ceftriaxone.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
Albany, New York, United States, 12204
- Albany Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18 years or older
- met ATS/ISDA criteria rule of CABP
- CABP requiring hospitalization and treatment with a IV antimicrobial
- anticipated hospitalization for > 48 hours
- received ceftaroline in combination with a macrolide (clarithromycin, or azithromycin) for > 48 hours within the first 24 hours after presentation to the hospital and must have remained on therapy for at least 48 hours after admission
- Pneumonia Patient Outcomes Research Team (PORT)risk class III or IV
Exclusion Criteria:
- CABP PORT Risk class I, II, III
- CABP requiring admission to an ICU
- CABP suitable for outpatient therapy with an oral microbial agent
- confirmed or suspected respiratory tract infection attributed to a source other than CABP pathogens
- noninfectious case of pulmonary infiltrates or pleural empyema
- infection with a pathogen know to be resistant to ceftaroline or epidemiological/ clinical context suggesting a high likelihood of a resistant pathogen
- previous therapy with another intravenous beta-lactam for CABP for between 24 and 96 hours prior to randomization
- receipt of chronic concomitant systemic steroids > 40 mg of prednisone equivalent
- significant hepatic disease
- hematologic disease
- Immunological disease
- history of a hypersensitivity reaction to beta-lactams
- pregnant or nursing females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achieving clinical stability
Time Frame: day 2
|
definition of clinically stable: temperature ≤37.8°C, heart rate ≤100 beats/min, systolic blood pressure ≥90 mm Hg, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% or pO2 ≥ 60 mm Hg on room air, and normal mental status; none of the following symptoms worsening: cough, dyspnea, chest pain, sputum production; and ≥ 1 of the aforementioned symptoms improving.
|
day 2
|
Achieving clinical stability
Time Frame: day 3
|
definition of clinically stable: temperature ≤37.8°C, heart rate ≤100 beats/min, systolic blood pressure ≥90 mm Hg, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% or pO2 ≥ 60 mm Hg on room air, and normal mental status; none of the following symptoms worsening: cough, dyspnea, chest pain, sputum production; and ≥ 1 of the aforementioned symptoms improving.
|
day 3
|
Achieving clinical stability
Time Frame: day 4
|
definition of clinically stable: temperature ≤37.8°C, heart rate ≤100 beats/min, systolic blood pressure ≥90 mm Hg, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% or pO2 ≥ 60 mm Hg on room air, and normal mental status; none of the following symptoms worsening: cough, dyspnea, chest pain, sputum production; and ≥ 1 of the aforementioned symptoms improving.
|
day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achieving clinical stability
Time Frame: day 5
|
definition of clinically stable: temperature ≤37.8°C, heart rate ≤100 beats/min, systolic blood pressure ≥90 mm Hg, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% or pO2 ≥ 60 mm Hg on room air, and normal mental status; none of the following symptoms worsening: cough, dyspnea, chest pain, sputum production; and ≥ 1 of the aforementioned symptoms improving.
|
day 5
|
Hospital Readmission
Time Frame: day 30
|
medical record review to note if subject re-admitted within past 30 days
|
day 30
|
All-cause mortality
Time Frame: day 30
|
medical record review to identify if subject mortality occured within past 30 days
|
day 30
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wayne Triner, DO, MPH, Albany Medical College
- Principal Investigator: Tom Lodise, PharmD, Albany College of Pharmacy and Health Sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3216
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Community Acquired Bacterial Pneumonia
-
PfizerCompletedPneumonia, Pneumococcal | Gram-positive Bacterial Infections | Community Acquired InfectionsUnited States, Slovakia, Spain, Taiwan
-
Zai Lab (Hong Kong), Ltd.RecruitingCommunity-acquired Bacterial PneumoniaUnited States
-
Melinta Therapeutics, Inc.Biomedical Advanced Research and Development AuthorityTerminatedCommunity-acquired Bacterial PneumoniaSpain, United States, Philippines, Hungary, United Kingdom, Bulgaria
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Bacterial PneumoniaUnited States, Canada
-
Clarametyx Biosciences, Inc.RecruitingCommunity-acquired Pneumonia | Bacterial PneumoniaUnited States
-
Paratek Pharmaceuticals IncCompletedCommunity-acquired PneumoniaUnited States
-
Paratek Pharmaceuticals IncActive, not recruitingCommunity-acquired Pneumonia | Bacterial PneumoniaBulgaria, Croatia, Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine
-
Durata Therapeutics Inc., an affiliate of Allergan...WithdrawnCommunity Acquired PneumoniaUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownCommunity Acquired PneumoniaChina
-
WockhardtACMCompletedCommunity-Acquired Bacterial Pneumonia (CABP)United States
Clinical Trials on Efficacy of ceftaroline
-
Poitiers University HospitalCompleted
-
Forest LaboratoriesCompleted
-
Forest LaboratoriesCompletedBacterial InfectionUnited States
-
Children's Hospital Medical Center, CincinnatiActive, not recruitingCystic FibrosisUnited States
-
Basim AsmarForest LaboratoriesUnknownVentriculoperitoneal Shunt | Cerebrospinal Fluid ShuntsUnited States
-
Baylor College of MedicineAllerganCompletedCeftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in ChildrenOsteomyelitis | Bone Infection | Hematogenously Acquired Staphylococcus Aureus OsteomyelitisUnited States
-
Hospices Civils de LyonCompletedAntibiotic Reaction | Bone and Joint InfectionFrance
-
Medical University of ViennaRecruitingInfection During Renal Replacement TherapyAustria
-
PfizerCompleted
-
Orlando Health, Inc.Forest LaboratoriesWithdrawnOsteomyelitis | Joint InfectionsUnited States